Trends in Biochemical Sciences
Volume 43, Issue 4, April 2018, Pages 227-229
SpotlightGenetic Vulnerability of GPCRs: A Call to Action
References (10)
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
Lancet
(2004)Pharmacogenomics of GPCR drug targets
Cell
(2018)Pharmacology and physiology of human adrenergic receptor polymorphisms
Annu. Rev. Pharmacol. Toxicol.
(2003)Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects
Am. J. Respir. Cell Mol. Biol.
(1993)Polymorphisms of the β2-adrenergic receptor determine exercise capacity in patients with heart failure
Circ. Res.
(2000)
There are more references available in the full text version of this article.
Cited by (2)
Personalized Medicine Through GPCR Pharmacogenomics
2022, Comprehensive PharmacologyHis452Tyr polymorphism in the human 5-HT<inf>2A</inf> receptor affects clozapine-induced signaling networks revealed by quantitative phosphoproteomics
2021, Biochemical PharmacologyCitation Excerpt :Single nucleotide polymorphisms resulting in the substitution of an amino acid in the primary structure of a given protein may confer alterations in its functionality at the physiological level. Particularly in the case of GPCRs, these polymorphisms could involve pharmacological implications such as alterations in the risk of developing a disease and/or alterations of the response to therapy [31]. One of the genetic variants of the human 5-HT2AR is a non-synonymous single nucleotide polymorphism consisting in the mutation C/T (rs6314) that results in the substitution His/Tyr at the position 452 of the amino acidic sequence of this protein.
© 2018 Elsevier Ltd. All rights reserved.